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ABSTRACT  
Background: Ventilator-associated pneumonia (VAP) is considered as the most common nosocomial infection in the 
intensive care unit (ICU) with high mortality rates. Hypoalbuminemia has been recognized as poor prognostic 
indicator in critically ill patients but its role in patients with VAP is not fully known. The aim of this study was to 
evaluate the role of initial serum albumin in predicting the mortality of patient with VAP.  
Method: We designed a retrospective study to analyze data from hospitalized patients with VAP between 2003 - 
2012 in Cipto Mangunkusumo Hospital, a tertiary hospital in Indonesia. Patients were grouped based on their initial 
serum albumin levels into: Group-1 (less than 2.7 g/dL), Group-2 (2.7 to 3.5 g/dL), and Group-3 (above 3.5 g/dL). We 
analyzed the hazard of in-hospital-mortality with cox proportional hazard model.  
Results: Out of 194 patients evaluated in this study, 95 patients (49%) were included in Group-1, 83 patients 
(42.8%) in Group-2, and 16 patients (8.2%) in Group-3. Overall mortality rate was 58.2%. The hazards of in-hospital- 
mortality in Group-1 and Group-2 were 2.48 (95% CI 1.07 to 5.74; p = 0.033) and 1.42 (95% CI 0.60 to 3.34; p = 0.43), 
respectively, compared to Group-3.  
Conclusion: Hypoalbuminemia increases the risk of mortality and initial serum albumin level should be considered as a 
predictor of mortality in every patient with VAP.  
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ABSTRAK  
Latar Belakang: Ventilator-associated pneumonia (VAP) merupakan infeksi nosokomial yang paling sering 
ditemukan di intensive care unit (ICU) dan memiliki angka mortalitas yang tinggi. Hipoalbuminemia telah lama 
diketahui sebagai petanda prognosis buruk pada pasien dengan penyakit kritis, namun peranannya pada pasien 
VAP belum jelas diketahui. Penelitian ini bertujuan untuk mengetahui peranan albumin serum inisial dalam 
memprediksi mortalitas pasien VAP.  
Metode: Kami melakukan penelitian kohort retrospektif dengan menganalisis data pasien VAP yang dirawat di  
Rumah Sakit Cipto Mangunkusumo selama kurun waktu tahun 2003 - 2012. Pasien dibagi menjadi tiga kelompok  
berdasarkan kadar albumin serum inisial: Grup-1 (kurang dari 2,7 g/dL), Grup-2 (2,7-3,5 g/dL), dan Grup-3  
(lebih dari 3,5 g/dL). Risiko mortalitas selama perawatan dianalisis dengan Cox proportional hazard model.  
Hasil: Dari 194 pasien yang diikutsertakan, sebanyak 95 (49%) pasien termasuk dalam Grup-1, 83 (42,8%)  
pasien termasuk dalam Grup-2, dan 16 (8,2%) pasien termasuk dalam Grup-3. Mortalitas selama perawatan  
terjadi pada 58,2% subjek. Rasio hazard terjadinya mortalitas untuk Grup-1 dan Grup-2 adalah 2,48 (IK 95%  
1,07 sampai 5,74; p = 0,033) dan 1,42 (IK 95% 0,60 sampai 3,34; p = 0,43) apabila dibandingkan dengan Grup-3.  
Simpulan: Adanya hipoalbuminemia akan meningkatkan risiko mortalitas. Kadar albumin serum inisial sebaiknya 
dipertimbangkan sebagai prediktor mortalitas pada pasien VAP. 
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INTRODUCTION 
 
Ventilator-associated   pneumonia (VAP)   is 
pneumonia  that  develops 48-72  hours  after  the 
use of m echanical ventilation.1 Rumende (2008) 
reported the incidence of VAP at Cipto Mangunkusumo  
Hospital, Jakarta (RSCM) by 36% with a mortality rate  
of 51. 4%.2 It is very important for every physician to  
understand the predictors of mortality as to facilitate  
clinical decision-making and the basis for education to  
patients and families. Until now, studies on predictors  
of mortality of VAP still show various results.3-5 
Albumin is a serum protein that plays a role  
in maintaining intravascular oncotic pressure and  
transporting  various  molecules  including  drugs.  
Hypoalbuminemia is often found in acute or chronic  
medical  condition.  In  addition  to  become  a  risk  
factor, hypo-albuminemia is also studied as one of  
the predictors of mortality in patients treated in  
ICU.6,7 Pinheiro found that hipoalbuminemia is one 
 
 
risks of mortality during treatment were analyzed using 
Cox proportional hazard models. This study has received 
ethics approval by Health Research Ethics Committee of 
the Faculty of Medicine, Universitas Indonesia. 
 
RESULTS 
 
During  the  study, 201  VAP  patients  were 
obtained. Seven patients were excluded because their  
data were incomplete. A total of 194 patients met  
inclusion criteria. Ninety five subjects (49%) were in  
Group-1, 83 subjects (42.8%) were in Group-2, and  
16 subjects (8.2%) were in Group-3. Characteristics of  
the subjects are presented in Table 1. Mean APACHE  
II scores obtained on the Group-1 was 15.4 (SD 7.5),  
Group-2 was 15.4 (SD 6.0), and Group- 3 was 13.6 (SD  
5.4). There was no significant difference in the mean  
APACHE II scores between each group (p> 0.05). 
 
Table 1. Subjects’ Characterictics 
Alive Dead 
independent predictor of mortality in ICU patients 
with Pseudomonas infection.8 However, the role of 
serum albumin predicting mortality in ICU patients 
with VAP is still unclear. 
This study aimed to determine the role of serum  
albumin in predicting mortality initials VAP patients. 
Characteristics 
Age (year), mean (SD) 
APACHE II, mean (SD) 
Male, n (%) 
Early onset, n (%) 
Surgical patients, n (%) 
n = 81 n = 113 
42,8 (15,3) 47,5 (17,1) 
12,9 (5,4) 16,9 (7,1) 
43 (53,1) 61 (54,0) 
40 (49,4) 59 (52,2) 
61 (75,3) 73 (64,6)  
Mortality during treatment occurred in 58.2% 
METHODS 
 
This  study  is  a  prognostic  study  with  a  
retrospective cohort design. The author conducted  
data analysis of VAP adult patients (aged 18 years or  
older) who were treated at RSCM during time period  
2003 to 2012. Subjects were selected consecutively.  
Data collected included demographic data, clinical,  
and initial serum albumin level at the time VAP  
diagnosis was made. Patients were grouped into three  
groups based upon their initial serum albumin levels,  
ie Group-1 (albumin less than 2.7 g/dL), Group-2  
(albumin 2.7 to 3.5 g/dL), and Group-3 (albumin more  
than 3.5 g/dL). Outcomes assessed were the condition  
of the patient at discharge from hospital, alive or dead. 
The data obtained from medical records were  
then converted into variables and analyzed using SPSS  
version 17.0. Categorical data were presented in the  
form of numbers and percentages. Numerical data  
with normal distribution were presented as means and  
standard deviations. Numerical data with not normal  
distribution were presented as medians and ranges. The 
subjects. The mortality hazard ratios of Group-1 and 
Group-2 were 2.48 (95% CI 1.07 to 5.74; p = 0.033) 
and 1.42 (95% CI 0.60 to 3.34; p = 0.43) compared 
to Group-3. Figure 1 shows the increase in mortality 
hazard ratio during hospitalization based on initial 
serum albumin levels. 
 
DISCUSSION 
 
High  mortality  rate  found  in  this  study  is  
influenced  by  various  factors.  Rumende (2008) 
showed lower mortality rate in ICU probably because 
of differences in sample sizes (194 vs 35 subjects) and 
length of the studies (10 vs 2 years).2 
Huang and Tseng in Taiwan found that the  
mortality rate was relatively low (50% and 44.8%).4,5  
One of the factors that may explain these differences  
is less than optimal management of VAP patients in  
this study. This is based on the difference between  
initial APACHE II scores of Huang and our studies.  
Huang reported a higher APACHE II score (23.2 (SD  
5.9)), however this study got higher mortality rate.  
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Another possibility is the use of different treatments 
and  facilities  between  developed  and  developing 
countries. Resende showed mortality in VAP patients 
was much higher in Brazil (78.8%).9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Comparisons among groups 
 
In this study, increase in mortality hazard was  
in accordance with decrease in serum albumin level.  
Decreased levels of albumin is proportional to increased  
mortality risk. Results obtained is in accordance with  
a meta-analysis conducted by Vincent to critically ill  
patients in ICU.6 Although there was no significant  
difference between Group 2 and Group-3, we found a  
trend towards an increase in mortality hazard due to  
decreased levels of serum albumin. This result might be  
related to albumin level cut-off values used in groups  
selection. Vincent found that albumin therapy (target =  
3.0 g/dL) reduced the risk of complication.6 This study  
did not distinguish serum albumin in Group-2 based  
on therapy targets. However, as shown in Figure 1, the  
increase in cumulative mortality hazard in Group-2  
tends to occur with increased duration of treatment. 
Vincent also reported that nutritional status and  
inflammation did not correlate with hypoalbuminemia  
and  poor  outcome.6  This  study  did  not  observe  
nutritional and inflammatory status of the subjects.  
APACHE II scores were related to clinical severity.  
We got no significant differences between the mean  
APACHE II score of each group. With consideration that  
serum albumin level is not included in the calculation of  
APACHE II score, the basic characteristics of the patients  
at the time of diagnosis can be balanced for comparison. 
To the best of our knowledge, there is still no study  
of hypoalbuminemia as a predictor of mortality in VAP 
 
 
patients. Bhattacharya found that hypoalbuminemia 
was not associated with mortality in ICU patients  
using mechanical ventilators in India.10 However, big  
difference in sample sizes, compared to our study, makes  
Bhattacharya’s results should be carefully interpreted. 
This is the first study in Indonesia to analyze the  
relationship hypoalbuminemia and mortality of VAP.  
Supported by a large sample, this study may represent  
a population of VAP in ICU patients in major cities of  
Indonesia. 
Nevertheless, retrospective cohort design used 
has limitations in reflecting the severity of the patient's 
clinical conditions appropriately. 
 
CONCLUSION 
 
Hypoalbuminemia increases the risk of mortality. 
Initial serum albumin level should be considered as a 
predictor of mortality in patients with VAP. 
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